- If you are wondering whether Alnylam Pharmaceuticals’ current share price lines up with its underlying worth, you are not alone. This article is designed to help you frame that question clearly.
- The stock last closed at US$327.36, with returns of a 3.5% decline over 7 days, a 7.7% decline over 30 days, an 18.2% decline year to date, but 38.1% over 1 year, 68.4% over 3 years and 138.3% over 5 years, which may have shifted how some investors view its risk and potential reward.
- Recent news flow around Alnylam has focused on its pipeline progress, regulatory milestones and partnerships, which often influences how investors think about future cash flows and risk. These headlines can quickly change sentiment, so it helps to separate the…
USDT liquidity drain puts crypto on the brink of a broad rout
February 26, 2026
